Fleming Island, FLNCT07662135Now EnrollingIRB Ready

Type 2 Diabetes Mellitus Clinical Trial in Fleming Island, FL

Access cutting-edge type 2 diabetes mellitus treatment through this phase 3 clinical trial at a research site in Fleming Island. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Fleming Island location

Preparing your pre-screening questions…

Expert Care in Fleming Island

Access type 2 diabetes mellitus specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related type 2 diabetes mellitus treatment provided free

Apply for This Fleming Island Location

Check if you qualify for this type 2 diabetes mellitus clinical trial in Fleming Island, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fleming Island

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fleming Island site if eligible
  4. 4Begin participation

About This Type 2 Diabetes Mellitus Study in Fleming Island

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Diagnosed with Type 2 Diabetes Mellitus for at least 90 days prior to screening
On SGTL2i or SGLT2i-naïve and other glucose lowering medication(s)
HbA1c value:
On stable dose of SGLT2i ≥ 7.0 % to ≤ 10.5% (53 to 91.3 mmol/mol)
SGLT2i-naive ≥ 7.5% to ≤ 10.5% (58 to 91.3 mmol/mol)
Impaired renal function
Body mass index (BMI) of ≥ 23 kg/m2 at screening
Stable body weight (self-reported or documented) for 90 days prior to screening

Exclusion Criteria

Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis
Severe congestive heart failure (New York Heart Association IV)
History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fleming Island?

Yes, this clinical trial (NCT07662135) has an active research site in Fleming Island, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Type 2 Diabetes Mellitus Treatment Options in Fleming Island, FL

If you're searching for type 2 diabetes mellitus treatment options in Fleming Island, FL, this clinical trial (NCT07662135) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fleming Island research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced type 2 diabetes mellitus specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all type 2 diabetes mellitus clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Fleming Island, FL

See all pulmonary embolism clinical trials recruiting in Fleming Island — not just this study.

Browse Pulmonary Embolism Trials in Fleming Island →

Browse More Trials by Condition

Pulmonary Embolism TrialsEssential Tremor TrialsType 2 Diabetes TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Fleming Island?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fleming Island, FL